CLASS I ONGOING Drug recall · Reported 5 Feb 2025 · FDA Enforcement Report

Prograf (tacrolimus) capsules, USP, 5 mg recalled by Astellas Pharma US

Astellas Pharma US is recalling Prograf (tacrolimus) capsules, USP, 5 mg, distributed nationwide in the US. The recall was initiated on 23 Dec 2024 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesLot# 0E3353D, Exp 03/31/2026
NDC0469-0607, 0469-0617, 0469-0657, 0469-3016, 0469-1230, 0469-1330
UPC0304690607731, 0304690657736, 0304691230501, 0304691330508, 0304690617730, 0304693016011
Quantity recalled14,340 100-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0211-2025
FDA event ID
96008
Recalling firm
Astellas Pharma US, Northbrook, IL
Brand
Prograf
Manufacturer
Astellas Pharma US, Inc.
Classification
Class I
Status
Ongoing
Recall initiated
23 Dec 2024
FDA classified
29 Jan 2025
Reported
5 Feb 2025
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Packaging Defects

Timeline

23 Dec 2024Recall initiated by company
29 Jan 2025Classified by FDA+37 days
5 Feb 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan, Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062, NDC 0469-0607-73.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Prograf (tacrolimus) capsules, USP, 5 mg recalled?

Yes. Astellas Pharma US recalled Prograf (tacrolimus) capsules, USP, 5 mg on 23 Dec 2024. The recall is Class I and its status is Ongoing. Recall number D-0211-2025.

Why was it recalled?

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Which lots are affected?

Lot# 0E3353D, Exp 03/31/2026

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Astellas Pharma US

All 5

Other Tacrolimus recalls

All 10